ClinicalTrials.gg
Enrolling by invitationNCT04145401Updated Mar 20, 2024

Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK

An observational study in Knee Osteoarthritis, sponsored by MicroPort Orthopedics Inc.. Enrolling by invitation at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
76th of 101
45 · median 100
Started
2020
with 53 others
Observational
101 of 796
18 open now
Primary completion
2033-05
later than 150 of 151 live
Registered
483rd of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 76th largest by planned enrollment of the 101 observational ones that give a count, is one of 54 that started in 2020, is one of 101 observational ones, reaches primary completion later than 150 of the 151 other live ones, and was the 483rd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its EVOLUTION® Revision CCK Tibia and EVOLUTION® Revision CCK Femur with EVOLUTION® CCK Tibial inserts. These type of studies are required by regulatory authorities for all devices that have been approved in Europe (EU) to evaluate the medium and long term clinical evidence. This study has been designed in accordance with MEDDEV2.12/2 rev 2 (European Medical Device Vigilance System) and ISO (International Organization for Standardization) 14155:2011 guidelines.

Read the detailed description

The objectives of this study are:

  1. To estimate the individual component survivorship of EVOLUTION® Revision Tibia, EVOLUTION® Revision CCK Femur, and EVOLUTION® CCK Tibial Insert.
  2. To find out the cumulative incidence of component revision of each component in this combination.
  3. To find out the functional outcome scores at early, midterm, and long-term follow-up.
03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • traumatic arthritis
  • avascular necrosis
  • rheumatoid arthritis
  • correction of functional deformity
  • revision procedures
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary TKA or Revision

Single study group with either newly or previously implanted patients with EVOLUTION® Revision Tibia and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Insert.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has previously undergone or currently has been determined to undergo a revision knee arthroplasty that requires the study (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert)
  2. Decision to perform the study index surgery with the required study components (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert) is pre-determined regardless of the research.
  3. Previously implanted subjects must be enrolled within 3 years (+6 months) of their study index surgery
  4. Willing and able to complete required study visits and assessments through the 10 year post-operative follow-up visit.

Bilateral subjects can have both TKAs enrolled in the study provided:

  1. the specified combination of components (EVOLUTION® Revision Tibial System and EVOLUTION® Revision CCK Femur with the EVOLUTION® CCK Tibial Insert) were implanted in both
  2. all other aspects of the Inclusion/Exclusion Criteria are satisfied
  3. enrollment does not exceed the subject count specified
  4. the subject agrees to a second document and data collection specific to the second TKA.

Exclusion criteria

Exclusion Criteria:

  1. Skeletally immature (less than 21 years of age) at time of implantation.
  2. Has an overt infection at the time of implantation.
  3. Has inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable.
  4. Currently enrolled in another clinical investigation which would affect the endpoints of this protocol.
  5. Has documented substance abuse issues.
  6. Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
  7. Currently incarcerated or has impending incarceration.
  8. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Interventions

  • DeviceRevision Knee implants

    Primary knee arthroplasty or a revision knee that requires a revision procedure.

06

What researchers measure

Primary outcomes

  1. Individual component survivorship

    Individual component survivorship for tibial base, femoral, and tibial insert at specified intervals out to 10 years follow-up.

    Time frame: 10 years post-operative

Secondary outcomes

  1. Patient Reported Outcomes- Questionnaires

    * functional scores for subjects, as assessed by Knee Injury and Osteoarthritis Outcome Score (KOOS), out to 10 years follow-up * functional scores for subjects, as assessed by EuroQol-5D-5L (EQ-5D-5L) Scores, out to 10 years follow-up * subject satisfaction measures with their Total Knee Arthroplasty (TKA) procedure using the Forgotten Joint Score * subject satisfaction measures with their TKA procedure using the Satisfaction Survey

    Time frame: 10 years post-operative

  2. Incidence of component revision

    the cumulative incidence of component revision at specified intervals will be determined out to 10 years follow-up

    Time frame: 10 years post-operative

  3. Radiolucencies

    the presence, zone, and the size of radiolucencies surrounding implanted components will be determined

    Time frame: 10 years post-operative

  4. Adverse Events and Adverse Device Effects

    characterization of adverse events and adverse device effects

    Time frame: 10 years post-operative

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for May 2033, 151 months after the start.

Of 220 observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 61. This study's planned 151 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Oct 30, 2019
StartActual
Sep 30, 2020
Primary completionEst.
May 1, 2033
CompletionEst.
Nov 1, 2033
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04145401
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Sep 30, 2020
Primary completion
May 1, 2033 (estimated)
Completion
Nov 1, 2033 (estimated)
Last update
Mar 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion